Adding perioperative apalutamide and ADT to radical prostatectomy reduced the risk of an oncologic event or death by 62% in high-risk prostate cancer.
|Poll|July 2, 2014
59-Year-Old Man Presents With Low Back Pain & Bone Lesion
Author(s)Cesar A. Moran, MD
A 59-year-old man presents with lower back pain. Diagnostic imaging reveals the presence of a lesion in the bone in the lower back area. A prostate and bone biopsy are performed. What is your diagnosis?
Advertisement
A 59-year-old man presents with lower back pain. Diagnostic imaging reveals the presence of a lesion in the bone in the lower back area. A prostate and bone biopsy are performed and results are shown below, respectively.
What is your diagnosis?
Advertisement
Related to this article
The phase 3 DeLLphi-305 trial may support tarlatamab plus durvalumab as a new standard-of-care frontline maintenance option in extensive-stage SCLC.
Full INTerpath-001 data at ESMO 2026 detail OS, subgroup, and safety results with intismeran plus pembrolizumab in resected stage IIB to IV melanoma.
In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.
“The more representation, the more people we have participating in clinical trials, the more applicable the data,” said Patricia A. Robinson, MD.
In the phase 3 TANGENT trial, an 8-week course of emactuzumab improved objective response rate vs placebo in patients with tenosynovial giant cell tumor.
In an exploratory KEYNOTE-B15 analysis, ctDNA clearance was higher with enfortumab vedotin plus pembrolizumab than with cisplatin and gemcitabine.
Subgroup analyses of the phase 3 RASolute 302 trial showed overall survival favored daraxonrasib over chemotherapy in metastatic pancreatic cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
INTerpath-001 Data Detail Survival, Subgroup, and Safety Findings in Melanoma
2
Top Poster Takeaways for Prostate Cancer From 2026 ESMO Congress
3
Tarlatamab Maintenance Combo Extends Survival in Extensive-Stage SCLC
4
Daraxonrasib Demonstrates Consistent Survival Benefit Across Subgroups in Pretreated mPDAC
5